Endocrine Abstracts

Castration-resistant prostate cancer (CRPC) develops after androgen deprivation therapy of advanced PC, often with metastatic growth in bone and very poor prognosis. Standard treatment is docetaxel, followed by androgen-synthesis (abiraterone) or androgen receptor inhibition, or treatment with the novel taxane cabazitaxel. Novel drugs are constantly under development and molecular properties of individual tumors will determine treatment effectiveness in individual cases. The a...